Literature DB >> 8983290

High molecular weight phospholipase A2 and fatty acids in human colon tumours and associated normal tissue.

A S Soydan1, I A Tavares, P K Weech, N M Temblay, A Bennett.   

Abstract

Human colon tumours usually form more prostaglandins (PGs) than associated normal tissues, but the mechanism(s) are not fully understood. We analysed fatty acid compositions, in particular arachidonate, and measured the amount and the activity of high molecular weight cytoplasmic phospholipase A2 (cPLA2) of these tissues. Total lipids extracted from homogenised surgical specimens were transesterified and fatty acids were analysed by gas chromatography. cPLA2 was separated by SDS-PAGE, Western-blotted, immunoblotted using a specific antibody to cPLA2 and semiquantified following enhanced chemiluminescence using a scanning densitometer. cPLA2 biological activity was also assayed using 1-stearoyl, 2-[1-14C]-arachidonyl, L-3-phosphatidylcholine. Compared with normal mucosa/submucosa, there was more total arachidonate in tumours (P < 0.01), and increased levels of cPLA2 occurred in 6 of 17 tumours. In conclusion, the higher amounts of tumour total arachidonate and the sometimes higher levels of cPLA2, might help to explain why some human colon tumours form increased amounts of PGs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8983290     DOI: 10.1016/0959-8049(96)00166-9

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

1.  Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.

Authors:  Katherine L Gill; J Brian Houston; Aleksandra Galetin
Journal:  Drug Metab Dispos       Date:  2012-01-24       Impact factor: 3.922

Review 2.  Roles of cPLA2alpha and arachidonic acid in cancer.

Authors:  Masako Nakanishi; Daniel W Rosenberg
Journal:  Biochim Biophys Acta       Date:  2006-09-15

3.  In vivo and in vitro studies of cytosolic phospholipase A2 expression in Helicobacter pylori infection.

Authors:  G Nardone; E L Holicky; J R Uhl; L Sabatino; S Staibano; A Rocco; V Colantuoni; B A Manzo; M Romano; G Budillon; F R Cockerill; L J Miller
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

4.  Group II and IV phospholipase A(2) are produced in human pancreatic cancer cells and influence prognosis.

Authors:  M Kashiwagi; H Friess; W Uhl; P Berberat; M Abou-Shady; M Martignoni; S E Anghelacopoulos; A Zimmermann; M W Büchler
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

5.  Reduced group IVA phospholipase A2 expression is associated with unfavorable outcome for patients with gastric cancer.

Authors:  Xia Zhang; Qiong Wu; Lu Gan; Guan-Zhen Yu; Rui Wang; Zi-Shu Wang; Jie-Jun Wang; Xi Wang
Journal:  Med Oncol       Date:  2013-01-10       Impact factor: 3.064

6.  Expression of inflammatory secretory phospholipase A2 and cytosolic phospholipase A2 in premalignant and malignant Barrett's oesophagus.

Authors:  Christine Lagorce-Pagès; François Paraf; Dominique Wendum; Antoine Martin; Jean-François Fléjou
Journal:  Virchows Arch       Date:  2004-03-25       Impact factor: 4.064

7.  Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer.

Authors:  Sung Chul Lim; Hoon Cho; Tae Bum Lee; Cheol Hee Choi; Young Don Min; Sung Soo Kim; Kyung Jong Kim
Journal:  Yonsei Med J       Date:  2010-09       Impact factor: 2.759

8.  Prognostic significance of cytosolic phospholipase A2 expression in patients with colorectal cancer.

Authors:  Young Sun Yoo; Sung Chul Lim; Kyung Jong Kim
Journal:  J Korean Surg Soc       Date:  2011-06-09

9.  Biphasic activation of extracellular signal-regulated kinase (ERK) 1/2 in epidermal growth factor (EGF)-stimulated SW480 colorectal cancer cells.

Authors:  Donghyun Joo; Jong Soo Woo; Kwang-Hyun Cho; Seung Hyun Han; Tae Sun Min; Deok-Chun Yang; Cheol-Heui Yun
Journal:  BMB Rep       Date:  2016-04       Impact factor: 4.778

10.  CXCR4 in Cancer and Its Regulation by PPARgamma.

Authors:  Cynthia Lee Richard; Jonathan Blay
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.